Leleesha Samaraweera
Overview
Explore the profile of Leleesha Samaraweera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Samaraweera L, Spengler B, Ross R
Oncol Rep
. 2017 Jun;
38(1):545-550.
PMID: 28560387
Neuroblastoma is a childhood cancer originating from embryonic neural crest cells. Amplification of the proto‑oncogene N-myc, seen in ~30% of neuroblastoma tumors, is a marker for poor prognosis. Recently discovered...
2.
Samaraweera L, Adomako A, Rodriguez-Gabin A, McDaid H
Sci Rep
. 2017 May;
7(1):1900.
PMID: 28507307
Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor. There is interest in evaluating alternate dosing schedules and novel combinations of pano for the treatment of upper aerodigestive and lung malignancies;...
3.
Hou J, Rodriguez-Gabin A, Samaraweera L, Hazan R, Goldberg G, Horwitz S, et al.
PLoS One
. 2016 Mar;
11(3):e0151750.
PMID: 26967738
No abstract available.
4.
Samaraweera L, Grandinetti K, Huang R, Spengler B, Ross R
BMC Cancer
. 2014 Jun;
14:309.
PMID: 24885481
Background: Neuroblastoma (NB) is the most common extracranial solid tumor in children. NB tumors and derived cell lines are phenotypically heterogeneous. Cell lines are classified by phenotype, each having distinct...
5.
Hou J, Rodriguez-Gabin A, Samaraweera L, Samaweera L, Hazan R, Goldberg G, et al.
PLoS One
. 2013 Feb;
8(2):e54103.
PMID: 23390495
While the clinical benefit of MEK inhibitor (MEKi)-based therapy is well established in Raf mutant malignancies, its utility as a suppressor of hyperactive MAPK signaling in the absence of mutated...